Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017


#41721

55pages

GlobalData

$ 2000

In Stock


GlobalData, the industry analysis specialist, has released its new report, “Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global melanoma market. The report identifies the key trends shaping and driving the global melanoma market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global melanoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. The global melanoma market was valued at $351m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 16.8% for the next eight years to reach $1,420m by 2017. The growth will primarily be driven by an increase in the disease incidence rate, an increase in awareness of the treatment options, an increase in the treatment seeking population and an influx of novel and efficient drugs. 

Scope

The report provides information on the key drivers and challenges of the melanoma market. Its scope includes:

  • Annualized global melanoma market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Anti-VEGF, B-cell lymphoma 2,Transmembrane glycoprotein NMB, mTOR inhibitor, BRAF Kinase inhibitor, MEK inhibitor, microtubule inhibits, Mitotic inhibitor and Cytotoxic agent.
  • Analysis of the current and future competition in the global melanoma market. Key market players covered are Abraxis BioScience, Inc., Glaxosmithkline, Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Oncolytics Biotech Inc., Merck & Co., Inc., and Pfizer Inc.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the melanoma therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global melanoma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global melanoma market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global melanoma market landscape? - Identify, understand and capitalize.
Table of Contents

1 Table of Contents 2

1.1 List of Tables 4
1.2 List of Figures 4

2 Melanoma: Introduction 5
2.1 Overview 5
2.2 GlobalData Pipeline Report Guidance 7

3 Mela.noma Therapeutics: Market Characterization 8

3.1 Overview 8
3.2 Melanoma Market Size 8
3.3 Melanoma Market Forecast and Compound Annual Growth Rate 10
3.4 Drivers and Barriers for the Melanoma Therapeutics Market 11
3.4.1 Drivers for the Melanoma Therapeutics Market 11
3.4.2 Barriers for the Melanoma Market 11
3.5 Opportunity and Unmet Need 12
3.6 Key Takeaway 13

4 Melanoma Market: Competitive Assessment 14
4.1 Overview 14
4.2 Strategic Competitor Assessment 14
4.3 Product Profile for the Major Marketed Products in the Melanoma Market 15
4.3.1 DTIC - Dome (Dacarbazine) 15
4.3.2 Proleukin (Aldesleukin) 16
4.3.3 Intro A (interferon alpha 2b) 18
4.4 Key Takeaway 21

5 Melanoma Market: Pipeline Assessment 22
5.1 Overview 22
5.2 Strategic Pipeline Assessment 22
5.3 Melanoma Therapeutics Market Promising Drugs under Clinical Development 24
5.4 Molecule Profile for Promising Drugs Under Clinical Development 25
5.4.1 PegIntron (Pegylated interferon alfa-2b) 25
5.4.2 Multiferon (Human Albumin) 26
5.4.3 Oncovex GMCSF (HSV DNA Vaccine) 27
5.4.4 PLX-4032 28
5.4.5 Ipilimumab (MDX-010, MDX-101) 29
5.4.6 Allovectin-7 30
5.5 Melanoma Market Clinical Pipeline by Mechanism of Action 31
5.5.1 Melanoma Market Phase III Clinical Pipeline 32
5.5.2 Melanoma Market Phase II Clinical Pipeline 33
5.5.3 Melanoma Market Phase I Clinical Pipeline 35
5.5.4 Melanoma Market Preclinical Pipeline 37
5.5.5 Melanoma Market Discovery Phase Pipeline 38
5.5.6 Melanoma Market List of Terminated Clinical Trials 38
5.6 Key Takeaway 39

6 Global Melanoma Market: Implications for Future Market Competition 40

7 Melanoma Market: Future Players in Melanoma Market 42

7.1 Introduction 42
7.2 Abraxis BioScience 43
7.2.1 Company Overview 43
7.2.2 Business Description 43
7.3 GlaxoSmithKline 43
7.3.1 Overview 43
7.3.2 Business Description 44
7.4 Bayer Schering Pharma AG 44
7.4.1 Overview 44
7.4.2 Business Description 44
7.5 Genta Incorporated 45
7.5.1 Overview 45
7.5.2 Business Description 45
7.6 Swedish Orphan International AB 46
7.6.1 Overview 46
7.7 Bristol-Myers Squibb 46
7.7.1 Overview 46
7.7.2 Business Description 46
7.8 Merck & Co., Inc. 47
7.8.1 Overview 47
7.8.2 Business Description 47
7.9 Oncolytics Biotech 48
7.9.1 Introduction 48
7.9.2 Business Discription 48

8 Melanoma Therapeutics Market: Appendix 49
8.1 Market Definitions 49
8.2 Abbreviations 49
8.3 Research Methodology 50
8.3.1 Coverage 50
8.3.2 Secondary Research 51
8.3.3 Forecasting 51
8.3.4 Primary Research 53
8.3.5 Expert Panel Validation 54
8.4 Contact Us 54
8.5 Disclaimer 54
8.6 Sources 55
Table 1: Melanoma Classification by Stage and Treatment 5
Table 2: Melanoma Therapeutics Market, Global, Revenue ($m), 2001-2009 9
Table 3: Melanoma Therapeutics Market, Global, Revenue Forecast ($m), 2009-2017 10
Table 4: Melanoma Therapeutics Market, Major Marketed Products Comparison, 2009 20
Table 5: Melanoma Therapeutics Market, Most Promising Drugs Under Clinical Development, 2009 24
Table 6: Melanoma Therapeutics Market, Phase III Clinical Pipeline,2009 32
Table 7: Melanoma Therapeutics Market,Phase II Clinical Pipeline, 2009 33
Table 8: Melanoma Therapeutics Market, Phase I Clinical Pipeline, 2009 35
Table 9: Melanoma Therapeutics Market, Preclinical Pipeline, 2009 37
Table 10: Melanoma Therapeutics Market, Discovery Pipeline, 2009 38
Table 11: Melanoma Therapeutics Market, List of Terminated Clinical Trials, 2009 38
Figure 1: Melanoma Therapeutics Market, Global, Market Revenue ($m), 20002009 9
Figure 2: Melanoma Therapeutics Market, Global, Revenue Forecast ($m), 2009-2017 10
Figure 3: Opportunity and Unmet Need in the Melanoma Market 12
Figure 4: Strategic Competitor Assessment 14
Figure 5: Melanoma Therapeutics Market, Technology Trends Analytics Framework 22
Figure 6: Melanoma Therapeutics Market, Technology Trends Analytics Framework, Description 23
Figure 7: Melanoma Therapeutics Market, Clinical Pipeline by Mechanism of Action (%) 31
Figure 8: Melanoma Therapeutics Market, Clinical Pipeline by Phase of Development (%), 32
Figure 9: Melanoma Therapeutics Market, Implications for Future Market Competition 40
Figure 10: Melanoma Therapeutics, Clinical Pipeline by Company, 2009 42
Figure 11: GlobalData Market Forecasting Model 53